Rocket Pharmaceuticals analyst consensus stays supportive, shares trade near recent lows
22.06.2026 - 19:21:55 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-22, 19:16.
Rocket Pharmaceuticals (US7731221062) carries a broadly positive analyst stance, with an overall Buy consensus and a wide gap between current price and average target on Nasdaq data. The focus today is squarely on that consensus picture and the implied upside potential.
What analysts say on RCKT
According to an overview on Investing.com, Rocket Pharma is covered by 11 analysts who collectively assign a Buy recommendation on the stock. The distribution is mixed, with 5 Buy ratings, 6 Hold ratings and 2 Sell ratings in the sample. MarketScreener similarly cites an average analyst target of about 9.39 to 9.39 US dollars, compared with a last quoted price in the mid 3 dollar range on Nasdaq. This sets Rocket Pharmaceuticals against a US biotech peer field that includes other gene therapy developers listed on the Nasdaq such as Bluebird bio and Sarepta Therapeutics.
Target prices and implied upside
The analyst target corridor for Rocket Pharmaceuticals is wide. Investing.com reports a 12?month low target of 3 US dollars, a mean target of 9.39 US dollars and a high estimate of 16 US dollars. Based on the cited average target and a spot price around 3.40 US dollars, the implied upside exceeds 170 percent in that data set. MarketScreener’s snapshot for Rocket points to a very similar average target, underlining that the consensus has not shifted materially in recent weeks. For context, the Rocket Pharmaceuticals shares have traded in a 52?week range between 2.40 and 5.45 US dollars, keeping the current level close to the lower half of that band.
All news and data on the Rocket Pharmaceuticals shares
Charts, past articles and regulatory releases give additional context on how Rocket Pharmaceuticals trades on Nasdaq and how analysts have adjusted their views over time.
The business behind Rocket
Rocket Pharmaceuticals develops gene therapies for rare and often lethal genetic diseases, with programs spanning lentiviral and adeno?associated virus platforms. The company describes itself as a late?stage biotechnology group with fully integrated research, manufacturing and clinical capabilities in the United States. Pipeline highlights include candidates targeting conditions such as Danon disease and Fanconi anemia, where current treatment options remain limited.
Where the shares trade today
The Rocket Pharmaceuticals shares (US7731221062) trade on Nasdaq under the ticker RCKT, last quoted at about 3.38 US dollars on 2026-06-22 at 11:01 Eastern, according to MarketBeat data. This places the company’s equity value in the low?hundreds?of?millions US?dollar range based on recent market capitalization snapshots.
Rocket Pharmaceuticals at a glance
- Company: Rocket Pharmaceuticals, Inc.
- ISIN: US7731221062
- WKN: A2N9A4
- Ticker: RCKT
- Trading venue: NASDAQ
- Price (as of 2026-06-22, 11:01): 3.38 USD
- Market cap: around 0.28 billion USD (as of 2026-06-22)
- Sector / industry: Biotechnology / Gene Therapy
- Index membership: formerly S&P Biotechnology Select Industry Index, removed in June 2026
- Next earnings date: not officially scheduled
This text is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. Historical data and analyst opinions are not a reliable indicator of future performance.
